Last updated: February 28, 2026
What are the case details and procedural posture?
- Parties: AbbVie Inc. (plaintiff) against Hetero Labs Limited (defendant)
- Case number: 1:24-cv-00151
- Jurisdiction: United States District Court for the District of Delaware
- Filing date: January 31, 2024
- Nature of dispute: Patent infringement relating to AbbVie's Humira (adalimumab) biosimilar technology
Hetero Labs filed a biosimilar application with the FDA for a version of Humira. AbbVie asserts that Hetero's biosimilar infringes on one or more patents licensed or owned by AbbVie. The complaint alleges patent infringement under the BPCIA, referencing U.S. Patent Nos. 8,916,157; 9,071,280; and 10,330,132, which cover formulations, manufacturing, and methods related to adalimumab.
What are the key patent issues?
- Patent validity: AbbVie claims Hetero's biosimilar violates patents covering the structure, formulation, and manufacturing process of Humira.
- Infringement claims: The complaint specifies potential direct infringement of the asserted patents by Hetero’s biosimilar candidate.
- Biosimilar patent dance timing: The case centers on whether Hetero complied with the notice and exchange of information requirements under the BPCIA.
- Remedies sought: An injunction against sale, damages for patent infringement, and a declaration of patent validity.
What are the procedural actions and timeline?
- Initial Complaint: Filed on January 31, 2024.
- Response deadline: Usually within 21 days; Hetero has not yet filed an answer.
- Preliminary disclosures: Expected per the Local Rules to include patent infringement contentions.
- Potential motions: Hetero may move to dismiss or transfer; AbbVie could seek a preliminary injunction.
How does this case compare with similar litigations?
Compared with previous biosimilar patent disputes, this case follows the typical pattern of patent infringement claims filed shortly after biosimilar NDA submission. Similar cases, such as Amgen v. Sandoz (D. Del., 2014), involved patent validity challenges and BPCIA-specific procedural issues.
Strategic considerations include:
- Patent durability due to the patent estate behind Humira.
- Likelihood of a stay pending inter partes review (IPR), though courts are increasingly skeptical of delays for biosimilar cases.
- Potential settlement or patent license negotiations if infringement is found.
What are the potential impacts?
- Market access: This case may delay Hetero’s biosimilar entry, affecting pricing and competition.
- Patent litigation trend: Adds to the chain of bioequivalent litigation post-FDA biosimilar approvals.
- Regulatory influence: The outcome could influence BPCIA litigation strategies and patent dispute resolutions.
Key legal questions remaining
- Will Hetero demonstrate compliance with BPCIA procedures or face sanctions?
- Are the asserted patents valid and enforceable?
- Will the case settle, or proceed to trial?
Key Takeaways
- This case exemplifies common patent disputes in the biosimilar industry, focusing on patent rights and BPCIA procedural compliance.
- The outcome could influence biosimilar market entry strategies for Hetero and similar companies.
- The courts are likely to scrutinize patent validity and infringement assertions closely, potentially leading to invalidation defenses or licensing agreements.
FAQs
-
What is the BPCIA?
The Biologics Price Competition and Innovation Act (BPCIA) established an abbreviated approval pathway for biosimilars, including procedures for patent resolution.
-
Will this case delay Hetero’s biosimilar launch?
Possibly. Patent disputes often result in temporary injunctions or stay motions that can delay market entry.
-
Can Hetero initiate an IPR?
Yes, but courts sometimes refuse stays pending IPR, especially if there is a likelihood of infringement.
-
Are the patents at risk of invalidation?
Patent validity defenses may include obviousness or lack of novelty, but validity is ultimately determined by the court.
-
What strategies might AbbVie pursue?
Seek injunctive relief, challenge Hetero’s compliance with BPCIA, and defend patent validity aggressively.
Sources:
[1] United States District Court for the District of Delaware. (2024). Litigation documents.
[2] Biologics Price Competition and Innovation Act of 2009 (BPCIA).
[3] Federal Trade Commission. (2021). Patent litigation strategies in biosimilars.
[4] Marketline. (2023). Humira biosimilar market analysis.
